Oslo, Norway, 24 February 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 10 February 2026 regarding the results of a subsequent offering of new shares (the "Subsequent Offering"), raising NOK 16,306,227 in gross proceeds.

The share capital increase relating to the Subsequent Offering has been registered today with the Norwegian Register of Business Enterprises. In total, 1,811,803 shares (the "Offer Shares") have been issued through the Subsequent Offering. The Company's new share capital is NOK 7,690,000.50, divided into 76,900,005 shares with a nominal value of NOK 0.10 each.

The Offer Shares are expected to be registered in the Norwegian Central Securities Depository (VPS) either today, 24 February 2026, or tomorrow, 25 February 2026.

Disclosure regulation:

This information is subject to a duty of disclosure pursuant to the Company's continuing obligations as a company listed on Euronext Growth Oslo.

For more information, please contact:

Gjest Breistein, CFO

+47 952 60 512

gjest.breistein@lytixbiopharma.com

About Lytix Biopharma

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.